CIK 0001601830 · Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464099738
- Phone
- (385) 269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-04 | Gibson Christopher Chief Executive Officer | Gift 10b5-1 | −20,000 | 954,229 | ||
| 2025-11-04 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −60,000 | 4,863,334 | ||
| 2025-10-23 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +100,000 | 1,054,229 | ||
| 2025-10-23 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −100,000 | $5.70 | $570K | 954,229 |
| 2025-10-23 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −100,000 | 4,923,334 | ||
| 2025-10-10 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +120,000 | 1,074,229 | ||
| 2025-10-10 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −100,000 | $6.04 | $604K | 974,229 |
| 2025-10-10 | Gibson Christopher Chief Executive Officer | Gift 10b5-1 | −20,000 | 954,229 | ||
| 2025-10-10 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −120,000 | 5,133,034 | ||
| 2025-10-01 | Dar Zavain Director | Grant or award | +2,941 | 138,758 | ||
| 2025-10-01 | Li Dean Y Director | Grant or award | +1,961 | 1,238,528 | ||
| 2025-09-25 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +100,000 | 1,054,229 | ||
| 2025-09-25 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −100,000 | $4.76 | $476K | 954,229 |
| 2025-09-25 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −0 | 5,253,034 | ||
| 2025-09-15 | Taylor Ben R Chief Financial Officer | Shares withheld for taxes | −7,057 | $4.83 | $34K | 804,169 |
| 2025-09-10 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +120,000 | 1,074,229 | ||
| 2025-09-10 | Gibson Christopher Chief Executive Officer | Sale 10b5-1 | −100,000 | $4.71 | $471K | 974,229 |
| 2025-09-10 | Gibson Christopher Chief Executive Officer | Gift 10b5-1 | −20,000 | 954,229 | ||
| 2025-09-10 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock 10b5-1 | −120,000 | 5,253,034 | ||
| 2025-08-26 | Gibson Christopher Chief Executive Officer | Conversion 10b5-1 | +100,000 | 1,054,229 |
Page 7 of 9 · 179 trades